K
Kathryn M. Kitrinos
Researcher at Research Triangle Park
Publications - 59
Citations - 3394
Kathryn M. Kitrinos is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Hepatitis B virus & HBeAg. The author has an hindex of 20, co-authored 52 publications receiving 2998 citations. Previous affiliations of Kathryn M. Kitrinos include GlaxoSmithKline & Durham University.
Papers
More filters
Journal ArticleDOI
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin,Edward Gane,Maria Buti,Nezam H. Afdhal,William Sievert,Ira M. Jacobson,Mary Kay Washington,George Germanidis,John F. Flaherty,Raul Aguilar Schall,Jeffrey D. Bornstein,Kathryn M. Kitrinos,G. Mani Subramanian,John G. McHutchison,E. Jenny Heathcote +14 more
TL;DR: In patients with chronic HBV infection, up to 5 years of treatment with tenofovir DF was safe and effective, and long-term suppression of HBV can lead to regression of fibrosis and cirrhosis.
Journal ArticleDOI
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Yun-Fan Liaw,I-Shyan Sheen,Chuan-Mo Lee,Ulus Salih Akarca,George V. Papatheodoridis,Florence Wong,Ting-Tsung Chang,Andrzej Horban,Chia Wang,Peter Kwan,Maria Buti,Martín Prieto,Thomas Berg,Kathryn M. Kitrinos,Ken Peschell,Elsa Mondou,David Frederick,Franck Rousseau,Eugene R. Schiff +18 more
TL;DR: All treatments were well tolerated in patients with decompensated liver disease due to CHB with improvement in virologic, biochemical, and clinical parameters.
Journal ArticleDOI
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Maria Buti,Naoky Tsai,Joerg Petersen,Robert Flisiak,Selim Gürel,Zahary Krastev,Raul Aguilar Schall,John F. Flaherty,Eduardo B. Martins,Prista Charuworn,Kathryn M. Kitrinos,G. Mani Subramanian,Edward Gane,Patrick Marcellin +13 more
TL;DR: Long-term TDF treatment was associated with sustained virologic, biochemical, and serologic responses, without resistance, and was well tolerated, with a low incidence of renal and bone events.
Journal ArticleDOI
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B
Kathryn M. Kitrinos,Amoreena Corsa,Yang Liu,John F. Flaherty,Andrea Snow-Lampart,Patrick Marcellin,Katyna Borroto-Esoda,Michael D. Miller +7 more
TL;DR: TDF monotherapy maintains effective suppression of HBV DNA through 288 weeks of treatment with no evidence of TDF resistance.
Journal ArticleDOI
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Andrea Snow-Lampart,Brandi J. Chappell,Maria Curtis,Yuao Zhu,Florence Myrick,James Schawalder,Kathryn M. Kitrinos,Evguenia S. Svarovskaia,Michael D. Miller,Jeff Sorbel,Jenny Heathcote,Patrick Marcellin,Katyna Borroto-Esoda +12 more
TL;DR: Tenofovir disoproxil fumarate is a nucleotide analogue with potent activity against human immunodeficiency virus type 1 and hepatitis B virus (HBV) and no nucleosid‐naive or nucleoside‐experienced patient developed HBV pol/RT mutations associated with TDF resistance after up to 144 weeks of exposure to TDF monotherapy.